Kenvue Inc traded at $18.16 this Monday March 9th, decreasing $0.23 or 1.25 percent since the previous trading session. Looking back, over the last four weeks, Kenvue Inc lost 0.87 percent. Over the last 12 months, its price fell by 24.08 percent. Looking ahead, we forecast Kenvue Inc to be priced at 17.83 by the end of this quarter and at 16.27 in one year, according to Trading Economics global macro models projections and analysts expectations.
Kenvue Inc. is a consumer health company. The Company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include Pain Care; Cough, Cold, and Allergy; and Other Self Care (Digestive Health; Smoking Cessation; Eye Care; and Other). The Skin Health and Beauty segment's product categories include face and body care and hair, sun, and others. The Essential Health segment's product categories include oral care, baby care and other essential health (women’s health, wound care, and other). Its differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, Aveeno, Zyrtec, and Nicorette. The Company has a global footprint through which it sells and distributes its product portfolio in more than 165 countries across its four regions. The four region consists of North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).